Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Clinical Trials
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Sep 2, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2022

Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 4, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2022

Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Aug 2, 2022

Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Jul 5, 2022

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Jul 1, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 8, 2022

Syros to Present at JMP Securities Life Sciences Conference

Jun 3, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2022

Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update

RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...27
    © 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Sitemap
    twitter logo linkedin logo